Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT06789224

NCT06789224
Completed Not Applicable

Who may be able to join

Who might be able to join this trial:

  • Your doctor (the investigator) has determined that you are a suitable candidate for a procedure where your own blood is collected and cleaned during surgery for possible reuse.
  • You have been diagnosed with one of the following cancers: prostate, gallbladder, bladder, endometrial (uterine lining), stomach, ovarian, pancreatic, colon or rectal, non-small cell lung cancer, peritoneal carcinomatosis (cancer spread to the lining of the abdomen), kidney, or liver cancer.
  • If you have one of the first group of cancers listed (not kidney or liver), and a tissue sample from your tumor is available or can be tested within 5 days of signing consent, a specific protein marker on your tumor cells (called EpCAM) should test positive.
  • If you have kidney or liver cancer, a tissue sample from your tumor must already be available and must have tested positive for the EpCAM protein marker before your surgery.
  • You are scheduled to have surgery to remove your tumor.
  • Your doctor expects that at least 400 mL (roughly a small cupful) of blood can be collected during your tumor surgery.
  • You have been rated as generally healthy enough for surgery, with an anesthesia risk score of 3 or below on a standard medical scale (confirm with trial site).

Who may not be able to join:

  • You have received certain additional cancer treatments (such as chemotherapy delivered directly into the abdomen during surgery, known as HIPEC) before the blood collection part of the procedure is finished.
  • You have a low level of a certain type of white blood cell called lymphocytes (confirm with trial site for specific levels).
  • You have a type of cancer that is not on the list above, particularly cancers that are unlikely to have the EpCAM protein marker.
  • You develop a serious bloodstream infection (sepsis) during surgery.
  • You have severe liver scarring (cirrhosis) rated at the highest level of severity on a standard medical scale (Child-Pugh score C).
  • Your blood platelet count (cells that help your blood clot) is below a certain low level (confirm with trial site for specific numbers).
  • You have a known allergy or medical reason to avoid a drug called Catumaxomab, or any of the other materials used in the blood collection and cleaning procedure.
  • You currently have an active COVID-19 infection confirmed by a positive PCR test before surgery.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
Lindis Bloodcare GmbH
Registry
clinicaltrials_gov
Start date
15 February 2022
Est. completion
25 November 2023

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

depletion of EpCAM-positive tumor cells

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov